These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 26215610)

  • 1. The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression.
    Belledant A; Hovington H; Garcia L; Caron P; Brisson H; Villeneuve L; Simonyan D; Têtu B; Fradet Y; Lacombe L; Guillemette C; Lévesque E
    Eur Urol; 2016 Apr; 69(4):601-609. PubMed ID: 26215610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Nadeau G; Bellemare J; Audet-Walsh É; Flageole C; Huang SP; Bao BY; Douville P; Caron P; Fradet Y; Lacombe L; Guillemette C; Lévesque E
    J Clin Endocrinol Metab; 2011 Sep; 96(9):E1550-7. PubMed ID: 21733997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.
    Margaillan G; Lévesque É; Guillemette C
    J Steroid Biochem Mol Biol; 2016 Jan; 155(Pt A):85-93. PubMed ID: 26385605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic variation of genes involved in dihydrotestosterone metabolism and the risk of prostate cancer.
    Setlur SR; Chen CX; Hossain RR; Ha JS; Van Doren VE; Stenzel B; Steiner E; Oldridge D; Kitabayashi N; Banerjee S; Chen JY; Schäfer G; Horninger W; Lee C; Rubin MA; Klocker H; Demichelis F
    Cancer Epidemiol Biomarkers Prev; 2010 Jan; 19(1):229-39. PubMed ID: 20056642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.
    Miyoshi Y; Uemura H; Umemoto S; Sakamaki K; Morita S; Suzuki K; Shibata Y; Masumori N; Ichikawa T; Mizokami A; Sugimura Y; Nonomura N; Sakai H; Honma S; Harada M; Kubota Y
    BMC Cancer; 2014 Sep; 14():717. PubMed ID: 25256077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UDP-glucuronosyltransferases and biochemical recurrence in prostate cancer progression.
    Grant DJ; Chen Z; Howard LE; Wiggins E; De Hoedt A; Vidal AC; Carney ST; Squires J; Magyar CE; Huang J; Freedland SJ
    BMC Cancer; 2017 Jul; 17(1):463. PubMed ID: 28673330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC
    du Toit T; Bloem LM; Quanson JL; Ehlers R; Serafin AM; Swart AC
    J Steroid Biochem Mol Biol; 2017 Feb; 166():54-67. PubMed ID: 27345701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer.
    Mahal BA; Yang DD; Wang NQ; Alshalalfa M; Davicioni E; Choeurng V; Schaeffer EM; Ross AE; Spratt DE; Den RB; Martin NE; Mouw KW; Orio PF; Choueiri TK; Taplin ME; Trinh QD; Feng FY; Nguyen PL
    Eur Urol; 2018 Aug; 74(2):146-154. PubMed ID: 29478736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4-month randomised trial in middle-aged men.
    Kjaer TN; Ornstrup MJ; Poulsen MM; Jørgensen JO; Hougaard DM; Cohen AS; Neghabat S; Richelsen B; Pedersen SB
    Prostate; 2015 Sep; 75(12):1255-63. PubMed ID: 25939591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy.
    McKiernan J; Donovan MJ; Margolis E; Partin A; Carter B; Brown G; Torkler P; Noerholm M; Skog J; Shore N; Andriole G; Thompson I; Carroll P
    Eur Urol; 2018 Dec; 74(6):731-738. PubMed ID: 30237023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single nucleotide polymorphism in ADIPOQ predicts biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Gu C; Qu Y; Zhang G; Sun L; Zhu Y; Ye D
    Oncotarget; 2015 Oct; 6(31):32205-11. PubMed ID: 26320190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
    Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
    Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dihydrotestosterone and testosterone levels in men screened for prostate cancer: a study of a randomized population.
    Gustafsson O; Norming U; Gustafsson S; Eneroth P; Aström G; Nyman CR
    Br J Urol; 1996 Mar; 77(3):433-40. PubMed ID: 8814852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum dihydrotestosterone examined by ultrasensitive LC-MS/MS as a predictor of benign prostatic hyperplasia or Gleason score 6 cancer in men with prostate-specific antigen levels of 3-10 ng/mL.
    Miyoshi Y; Uemura H; Suzuki K; Shibata Y; Honma S; Harada M; Kubota Y
    Andrology; 2017 Mar; 5(2):262-267. PubMed ID: 27813361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
    Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
    Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression.
    Lévesque E; Labriet A; Hovington H; Allain ÉP; Melo-Garcia L; Rouleau M; Brisson H; Turcotte V; Caron P; Villeneuve L; Leclercq M; Droit A; Audet-Walsh E; Simonyan D; Fradet Y; Lacombe L; Guillemette C
    Br J Cancer; 2020 Mar; 122(7):1068-1076. PubMed ID: 32047296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients.
    Ravindran A; Krieger KL; Kaushik AK; Hovington H; Mehdi S; Piyarathna DWB; Putluri V; Basil P; Rasaily U; Gu F; Dang T; Choi JM; Sonavane R; Jung SY; Wang L; Mehra R; Weigel NL; Putluri N; Rowley DR; Palapattu GS; Guillemette C; Lacombe L; Lévesque É; Sreekumar A
    Cells; 2022 Jul; 11(15):. PubMed ID: 35954173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
    Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and characterization of the UGT2B28 cDNA encoding a novel human steroid conjugating UDP-glucuronosyltransferase.
    Lévesque E; Turgeon D; Carrier JS; Montminy V; Beaulieu M; Bélanger A
    Biochemistry; 2001 Apr; 40(13):3869-81. PubMed ID: 11300766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.